306
R. M. KAMP and H. HIRANO
1:El1ol l
s: R~s Iduc J
e.oo I
6 . 00 ~
~ . o~
2,OC
Q,oa :~{r-------------------------a. DO
6,00
00
00
O.O~
J.e
: E C
6 ?.!': !,.,
--~.e.oc
0 . 00
6.0C
~.OO
Loe
'; .OC
, ,cc
0,00
o DC
l.O
6C
9.0
!2Ci
15. .0
1 ;1
8 . 00
e.o~
6.00
6,00
p
~,oo
-l ,OO
L
2.00
2.0C
0,00
O. DC
),0
9 0
12 .0
);.0 18.0
9.0
) 0
15 .0
I~ .O
.; ; Kc5 ldu·· 2
L
I
I
" r
. _ .--)-,. n ---:- ,.;
Fig. 22.1. Amino acid sequence of neurotensin after deblocking with deblocking aminopeptidase
(DAP). 50 III of 50mM ethylmorpholine buffer pH 8.0 were added to 100 pmol neurotensin in 50 III
30 % pyridin. Enzyme: substrate ratio 1:1, cleavage time nh, temperature 50°C. Deblocked neurotensin was sequenced using Procise Sequencer (Applied Biosystems, USA). The sequence KPRRPY corresponds to neurotensin after deblocking with DAP and the sequence MVDYLL corresponds to intact
DAP, which was used in high substrate: enzyme ratio 1 : I. It is the reason for simuitaniously identification of deblocking enzyme DAP and neurotensin during amino acid sequence analysis